Show simple item record

dc.contributor.authorDennis, Michael
dc.contributor.authorDavies, Michelle
dc.contributor.authorOliver, S
dc.contributor.authorD'Souza, R
dc.contributor.authorPike, L
dc.contributor.authorStockman, P
dc.date.accessioned2012-12-05T16:31:51Z
dc.date.available2012-12-05T16:31:51Z
dc.date.issued2012-09
dc.identifier.citationPhase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. 2012, 70 (3):461-9 Cancer Chemother Pharmacolen_GB
dc.identifier.issn1432-0843
dc.identifier.pmid22864876
dc.identifier.doi10.1007/s00280-012-1939-2
dc.identifier.urihttp://hdl.handle.net/10541/254586
dc.description.abstractBarasertib (AZD1152) is a pro-drug that rapidly undergoes phosphatase-mediated cleavage in serum to release barasertib-hQPA, a selective Aurora B kinase inhibitor that has shown preliminary activity in clinical studies of patients with acute myeloid leukemia (AML). The pharmacokinetic (PK), metabolic and excretion profiles of barasertib and barasertib-hQPA were characterized in this open-label Phase I study.
dc.language.isoenen
dc.rightsArchived with thanks to Cancer chemotherapy and pharmacologyen_GB
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInfusions, Intravenous
dc.subject.meshLeukemia, Myeloid, Acute
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPhosphoric Acid Esters
dc.subject.meshProdrugs
dc.subject.meshProtein-Serine-Threonine Kinases
dc.subject.meshQuinazolines
dc.subject.meshRemission Induction
dc.subject.meshTime Factors
dc.subject.meshTreatment Outcome
dc.titlePhase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.en
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, Manchester, UK. mike.dennis@christie.nhs.uken_GB
dc.identifier.journalCancer Chemotherapy and Pharmacologyen_GB
html.description.abstractBarasertib (AZD1152) is a pro-drug that rapidly undergoes phosphatase-mediated cleavage in serum to release barasertib-hQPA, a selective Aurora B kinase inhibitor that has shown preliminary activity in clinical studies of patients with acute myeloid leukemia (AML). The pharmacokinetic (PK), metabolic and excretion profiles of barasertib and barasertib-hQPA were characterized in this open-label Phase I study.


This item appears in the following Collection(s)

Show simple item record